These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 18428503)

  • 1. Reducing gene expression in the brain via antisense methods.
    Ouagazzal AM; Tepper JM; Creese I
    Curr Protoc Neurosci; 2001 May; Chapter 5():Unit 5.4. PubMed ID: 18428503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient in vivo delivery of antisense oligonucleotide to choroid plexus.
    Piao W; Nishina K; Yoshida-Tanaka K; Kuwahara H; Nishina T; Sakata M; Mizusawa H; Yokota T
    J Med Dent Sci; 2013 Mar; 60(1):9-16. PubMed ID: 23917958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.
    Senn C; Hangartner C; Moes S; Guerini D; Hofbauer KG
    Eur J Pharmacol; 2005 Oct; 522(1-3):30-7. PubMed ID: 16213482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.
    Schlingensiepen R; Goldbrunner M; Szyrach MN; Stauder G; Jachimczak P; Bogdahn U; Schulmeyer F; Hau P; Schlingensiepen KH
    Oligonucleotides; 2005; 15(2):94-104. PubMed ID: 15989424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides fail to inhibit the expression of central beta adrenergic receptors.
    Zhang K; O'Donnell JM
    Res Commun Mol Pathol Pharmacol; 1997 Jan; 95(1):21-32. PubMed ID: 9055346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
    Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
    J Neurosurg; 1998 Apr; 88(4):734-42. PubMed ID: 9525721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System.
    Chen Y; Mazur C; Luo Y; Sun L; Zhang M; McCampbell A; Tomassy GS
    J Vis Exp; 2019 Oct; (152):. PubMed ID: 31736489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides in the treatment of bladder cancer.
    Glackin AJ; Gray SB; Johnston SR; Duggan BJ; Williamson KE
    Expert Opin Biol Ther; 2005 Jan; 5(1):67-77. PubMed ID: 15709910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense Noggin oligodeoxynucleotide administration decreases cell proliferation in the dentate gyrus of adult rats.
    Fan XT; Xu HW; Cai WQ; Yang H; Liu S
    Neurosci Lett; 2004 Aug; 366(1):107-11. PubMed ID: 15265600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine inhibition in rat stab wound brain injury using antisense oligodeoxynucleotides.
    Ghirnikar RS; Lee YL; Li JD; Eng LF
    Neurosci Lett; 1998 May; 247(1):21-4. PubMed ID: 9637400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-labeled antisense oligodeoxynucleotides in the rat.
    Yee F; Ericson H; Reis DJ; Wahlestedt C
    Cell Mol Neurobiol; 1994 Oct; 14(5):475-86. PubMed ID: 7621508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disinhibition from opioid influence augments hypothalamic neuropeptide Y (NPY) gene expression and pituitary luteinizing hormone release: effects of NPY messenger ribonucleic acid antisense oligodeoxynucleotides.
    Xu B; Sahu A; Kalra PS; Crowley WR; Kalra SP
    Endocrinology; 1996 Jan; 137(1):78-84. PubMed ID: 8536645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense technology: a selective tool for gene expression regulation and gene targeting.
    Sahu NK; Shilakari G; Nayak A; Kohli DV
    Curr Pharm Biotechnol; 2007 Oct; 8(5):291-304. PubMed ID: 17979727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Responsive changes to MPTP in rats with DAT inhibited by antisense oligonucleotides].
    Xu YM; Tao EX; Ding XJ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):236-9. PubMed ID: 18393256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain.
    Chauhan NB
    Antisense Nucleic Acid Drug Dev; 2002 Oct; 12(5):353-7. PubMed ID: 12477284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of adjuvant arthritis using microencapsulated antisense NF-κB oligonucleotides.
    Akhavein N; Oettinger CW; Gayakwad SG; Addo RT; Bejugam NK; Bauer JD; Do D; Pollock SH; D'souza MJ
    J Microencapsul; 2009 May; 26(3):223-34. PubMed ID: 18666015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of antisense to study gene expression. Introduction.
    Erickson RP
    Methods; 1999 Jul; 18(3):241-3. PubMed ID: 10454981
    [No Abstract]   [Full Text] [Related]  

  • 18. Oligodeoxynucleotides induce brain inflammation in rats when infused intracerebroventricularly.
    Elepfandt P; Rupprecht S; Schöning-Burkhardt B; Volk HD; Woiciechowsky C
    Neurosci Lett; 2002 Apr; 322(2):107-10. PubMed ID: 11958855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine-induced behaviors in the rat.
    Rajakumar N; Laurier L; Niznik HB; Stoessl AJ
    Synapse; 1997 Jul; 26(3):199-208. PubMed ID: 9183809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake of circulating insulin-like growth factor-I into the cerebrospinal fluid of normal and diabetic rats and normalization of IGF-II mRNA content in diabetic rat brain.
    Armstrong CS; Wuarin L; Ishii DN
    J Neurosci Res; 2000 Mar; 59(5):649-60. PubMed ID: 10686593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.